About This Webinar
The keys to a successful screening approach lie in identifying a disease early, before symptoms begin, and for those diseases where intervention is effective. Colorectal cancer is a leading cause of cancer deaths, while being highly treatable in early stages. Today, 1 in 3 eligible adults do not complete recommended colorectal cancer screening because methods can be unpleasant, time-consuming and difficult to complete.
Despite longstanding recommendations for CRC screening and non-invasive options being available for over a decade, many health care organizations struggle to improve screening rates. Most patients prefer a blood test that can be completed at any doctor’s visit, highlighting a key opportunity for a blood-based approach to CRC screening.
This webinar discusses the clinical rationale, evidence and opportunities for blood-based colorectal cancer screening. The Shield test from Guardant Health is the first blood-based test approved by the FDA for primary colorectal cancer screening. The FDA approval was based on results of ECLIPSE, a 20,000+-patient registrational study evaluating the performance of the test for detecting CRC in average-risk adults. NCCN guidelines now recommend Shield blood-based screening for CRC. Shield offers an accurate, easy-to-complete, blood-based approach to cancer screening with the potential to improve screening rates and, ultimately, save more lives.
Attendees Will Learn About
- The rationale and challenges associated with colorectal cancer screening
- The clinical evidence supporting Guardant Shield, a blood-based cancer screening test
- The regulatory and policy opportunities and implications for a blood-based colorectal cancer screening option for health plans and their members
